Holding
In Apotex, Inc. v. Auspex Pharms., Inc., IPR2021-01507,
Paper 9 (P.T.A.B. March 9, 2022) ("Institution
Decision"), the Patent Trial and Appeal Board
("PTAB") exercised its discretion under 35 U.S.C. §
325(d) to deny institution of Apotex's petition for inter
partes review ("IPR").
Background
Apotex (hereinafter "Petitioner") filed an IPR
petition challenging claims 1-3 of Auspex's (hereinafter
"Patent Owner") U.S. Pat. No. 8,524,733. Claims 1 and 2
are compound claims, while claim 3 is a composition claim. The
claims are directed to "a specific deuteration
pattern in tetrabenazine that ... does not involve deuteration of
the carbon-hydrogen bonds of the carbonyl group, the isopropyl
group, or any other carbon-hydrogen position in the molecule."
Institution Decision at *6 (emphasis in original).